Moberg Pharma’s rights issue of MSEK 100 is oversubscribed – subscription rate 130%
STOCKHOLM, 1 September 2023. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the rights issue of units, consisting of ordinary shares and warrants, with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 28 June 2023 and approved by an Extraordinary General Meeting on 8 August 2023. The outcome of the Rights Issue shows that subscription with support of unit rights and applications for subscription of units without support of unit rights in total correspond to approximately 130 percent of the units offered for subscription. 16,130,585 units were subscribed for with support of unit rights, corresponding to approximately 92 percent of the Rights Issue. Additionally, applications for subscription of 6,565,433 units without support of unit rights have been received, corresponding to approximately 38 percent of the Rights Issue. Consequently, persons who only applied for subscription of units without support of unit rights will not be allocated units in the Rights Issue. Thus, the Rights Issue is fully subscribed, and no issue guarantors are used. Moberg Pharma will receive approximately SEK 100 million before deduction for transaction costs.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN MOBERG PHARMA AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.
“I would like to thank existing and new investors for their confidence in this rights issue. We are pleased to have secured the funding and look forward to fully devoting our time towards realizing our business goals, including the commercial launch planned to start in our home market Sweden as soon as possible. Moberg Pharma is in an exciting phase after MOB-015 was recommended for market approval in 13 European countries in June this year and we have already managed to get national approval in several of these markets,” says Moberg Pharma’s CEO Anna Ljung.
In the Rights Issue, 17,470,149 units are issued, corresponding to 17,470,149 ordinary shares and 17,470,149 warrants of series 2023:1. Allotment of units subscribed for without support of unit rights has been made in accordance with the principles set out in the prospectus that the Company published on 14 August 2023. Notice of the allotment is provided by means of a contract note, which is distributed to each subscriber. Units shall be paid for in accordance with the instructions on the contract note. Nominee registered shareholders receive notice of the allotment in accordance with the procedures of the respective nominee. Only those who will receive allotment will be informed.
Following registration of the Rights Issue with the Swedish Companies Registration Office, the Company’s share capital will increase by SEK 17,470,149.867306 to a total of SEK 27,743,083.377306. The number of shares in the Company will increase by 17,470,149 to a total of 27,743,082. This entails a dilution effect of approximately 63 percent. If all warrants of series 2023:1 are exercised to subscribe for new ordinary shares in the Company, the number of shares will increase by an additional 17,470,149 shares and the share capital will increase by an additional amount of SEK 17,470,149.867306. Trading in paid subscribed unit (BTU) takes place on Nasdaq Stockholm up to approximately two bank days after the registration of the Rights Issue with the Swedish Companies Registration Office. Registration of the Rights Issue is estimated to take place around week 38, 2023. Thereafter, BTU will be converted into ordinary shares and warrants of series 2023:1.
Advisors
Vator Securities is acting as Sole Global Coordinator and Advokatfirman Schjødt is legal advisor to Moberg Pharma in connection with the Rights Issue.
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Moberg Pharma in any jurisdiction, either from Moberg Pharma or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus regarding the Rights Issue described in this press release has been registered with the Swedish Financial Supervisory Authority and is kept available at, inter alia, Moberg Pharma's website.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq Stockholm’s rules for issuers.
For additional information, please contact:
Anna Ljung, CEO, telephone: 070 - 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, telephone: 076 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se
About this information
This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 12:15 CEST on 1 September 2023.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).